Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.

  title={Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.},
  author={Luc J. Farmer and Mark W. Ledeboer and Thomas C Hoock and Michael J. Arnost and Randy S. Bethiel and Youssef L. Bennani and James J Black and Christopher L Brummel and Ananthsrinivas Chakilam and Warren A. Dorsch and Bin Fan and John E. Cochran and Summer M. Halas and E. Michael Harrington and James K. Hogan and David Blais Howe and Hui Huang and Dylan H Jacobs and Leena M Laitinen and Shengkai Liao and Sudipta Mahajan and Valerie Marone and Gabriel Martinez-Botella and Pamela M. McCarthy and David Messersmith and Mark N. Namchuk and Linda Oh and Marina S Penney and Albert C. Pierce and Scott A. Raybuck and Arthur Rugg and Francesco G Salituro and Kumkum Saxena and Dean E. Shannon and Dina Shlyakter and Lora L Swenson and Shouceng Tian and Christopher Town and Jian Wang and Tiansheng Wang and M Woods Wannamaker and Raymond J. Winquist and Harmon J. Zuccola},
  journal={Journal of medicinal chemistry},
  volume={58 18},
While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies. We screened our compound library against JAK3, a key signaling kinase in… CONTINUE READING


Publications citing this paper.


Publications referenced by this paper.

Selective inhibitors of the Janus kinase Jak 3 - Are they effective ?

  • G. Thoma, P. Druckes, H.-G. Zerwes
  • Bioorg . Med . Chem . Lett .
  • 2014

Similar Papers

Loading similar papers…